Sally L. Shirran

1.8k citations

54 papers · 1.3k indexed · h-index 20

Molecular Biology top 10%
Pharmacology top 2%
Pediatrics, Perinatology and Child Health top 10%
Oncology
Organic Chemistry

Co-authors: Catherine H. Botting James H. Naismith Jesko Koehnke Wael E. Houssen Marcel Jaspars Andrew F. Bent Greg Mann Perdita E. Barran
Topics: RNA modifications and cancer (6 papers)Microbial Natural Products and Biosynthesis (5 papers)Neurogenetic and Muscular Disorders Research (5 papers)
Cited by: Pharmacology Molecular Biology Biotechnology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United Kingdom United States Germany

In The Last Decade

Sally L. Shirran

54 papers receiving 1.3k citations

Peers

Countries citing papers authored by Sally L. Shirran

Since Specialization

Citations

This map shows the geographic impact of Sally L. Shirran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally L. Shirran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally L. Shirran more than expected).

Fields of papers citing papers by Sally L. Shirran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally L. Shirran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally L. Shirran. The network helps show where Sally L. Shirran may publish in the future.

Co-authorship network of co-authors of Sally L. Shirran

This figure shows the co-authorship network connecting the top 25 collaborators of Sally L. Shirran. A scholar is included among the top collaborators of Sally L. Shirran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally L. Shirran. Sally L. Shirran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cryo-EM structure of the conjugation H-pilus reveals the cyclic nature of the TrhA pilin 2025 ·Proceedings of the National Academy of Sciences ·(unknown),Joshua L. C. Wong,(unknown),Sally L. Shirran,(unknown),(unknown),(unknown),Carlos Balsalobre,Ravi R. Sonani,Abigail Clements,Edward H. Egelman,Gad Frankel,Konstantinos Beis	1
2	Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells 2024 ·Neuromuscular Disorders ·(unknown),Ian Holt,Sharon J. Brown,Silvia A. Synowsky,Sally L. Shirran,Heidi R. Fuller	2
3	Antiviral type III CRISPR signalling via conjugation of ATP and SAM 2023 ·Nature ·(unknown),Ville Hoikkala,Sabine Grüschow,Shirley Graham,Sally L. Shirran,Malcolm F. White	26
4	Unusual peptide-binding proteins guide pyrroloindoline alkaloid formation in crocagin biosynthesis 2023 ·Nature Chemistry ·Sebastian Adam,(unknown),Andreas Klein,Carsten Volz,William Mullen,Sally L. Shirran,Brian O. Smith,Olga V. Kalinina,Rolf Müller,Jesko Koehnke	19
5	Carbapenem-Only Combination Therapy against Multi-Drug Resistant Pseudomonas aeruginosa: Assessment of In Vitro and In Vivo Efficacy and Mode of Action 2022 ·Antibiotics ·Brendan J. MacKay,Benjamin J. Parcell,Sally L. Shirran,Peter J. Coote	1
6	Tumour‐associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles 2022 ·Immunology ·(unknown),(unknown),(unknown),(unknown),Peter Thorpe,Silvia A. Synowsky,Sally L. Shirran,Simon J. Powis	10
7	The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap 2022 ·Cells ·Sharon J. Brown,Rachel Kline,Silvia A. Synowsky,Sally L. Shirran,Ian Holt,(unknown),Peter Claus,Brunhilde Wirth,Thomas M. Wishart,Heidi R. Fuller	6
8	Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS 2022 ·Journal of Proteomics ·(unknown),(unknown),Silvia A. Synowsky,Margaret R. Dunne,(unknown),(unknown),(unknown),Noel E. Donlon,Cliona Lorton,Jacintha O’Sullivan,John V. Reynolds,Peter D. Caie,Sally L. Shirran,Andy G. Lynch,Alan J. Stewart,Swati Arya	3
9	Quantitative proteomic profiling of the rat substantia nigra places glial fibrillary acidic protein at the hub of proteins dysregulated during aging: Implications for idiopathic Parkinson's disease 2020 ·Journal of Neuroscience Research ·Yolanda Gómez‐Gálvez,Heidi R. Fuller,Silvia A. Synowsky,Sally L. Shirran,Monte Gates	5
10	Adverse effects of Δ9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development 2020 ·JCI Insight ·(unknown),(unknown),Daniela Calvigioni,(unknown),Roman A. Romanov,(unknown),Gert Lübec,Sally L. Shirran,Catherine H. Botting,Siegfried Kasper,Geoffrey W. Guy,Roy Gray,Vincenzo Di Marzo,Tibor Harkany,Erik Keimpema	15
11	Neurochondrin interacts with the SMN protein suggesting a novel mechanism for spinal muscular atrophy pathology 2018 ·Journal of Cell Science ·(unknown),(unknown),Sally L. Shirran,Ewout J. N. Groen,Thomas H. Gillingwater,Catherine H. Botting,Judith Sleeman	12
12	Two independent proteomic approaches provide a comprehensive analysis of the synovial fluid proteome response to Autologous Chondrocyte Implantation 2018 ·Arthritis Research & Therapy ·Charlotte Hulme,E. Lynette Wilson,Heidi R. Fuller,Sally Roberts,James B. Richardson,(unknown),Mandy J. Peffers,Sally L. Shirran,Catherine H. Botting,Karina T. Wright	6
13	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases 2017 ·DNA repair ·Nicholas W. Ashton,Nicolas Paquet,Sally L. Shirran,Emma Bolderson,(unknown),(unknown),(unknown),Roland Gamsjaeger,Liza Cubeddu,Catherine H. Botting,Pamela M. Pollock,Kenneth J. O’Byrne,Derek J. Richard	14
14	Contaminants in commercial preparations of ‘purified’ small leucine-rich proteoglycans may distort mechanistic studies 2016 ·Bioscience Reports ·Sharon J. Brown,Heidi R. Fuller,Philip R. Jones,Bruce Caterson,Sally L. Shirran,Catherine H. Botting,Sally Roberts	2
15	Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development 2016 ·Frontiers in Cellular Neuroscience ·Heidi R. Fuller,Berhan Mandefro,Sally L. Shirran,(unknown),(unknown),Catherine H. Botting,Glenn E. Morris,Dhruv Sareen	55
16	Miswiring the brain: 9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway 2014 ·The EMBO Journal ·Giuseppe Tortoriello,Caroline Morris,Alán Alpár,János Fuzik,Sally L. Shirran,Daniela Calvigioni,Erik Keimpema,Catherine H. Botting,Kirstin Reinecke,Thomas Herdegen,Michael J. Courtney,Yasmin L. Hurd,Tibor Harkany	174
17	Kdm3a lysine demethylase is an Hsp90 client required for cytoskeletal rearrangements during spermatogenesis 2014 ·Molecular Biology of the Cell ·(unknown),(unknown),Peri Tate,Andrew J. Finch,Joseph Shaw,Anne Seawright,(unknown),Catherine H. Botting,Sally L. Shirran,Ian R. Adams,Ian J. Jackson,Veronica van Heyningen,Patricia L. Yeyati	30
18	The Cyanobactin Heterocyclase Enzyme: A Processive Adenylase That Operates with a Defined Order of Reaction 2013 ·Angewandte Chemie ·Jesko Koehnke,Andrew F. Bent,David Zollman,(unknown),Wael E. Houssen,Xiaofeng Zhu,Greg Mann,Tomáš Lébl,(unknown),Sally L. Shirran,Catherine H. Botting,Marcel Jaspars,Ulrich Schwarz‐Linek,James H. Naismith	15
19	An Enzymatic Route to Selenazolines 2013 ·ChemBioChem ·Jesko Koehnke,(unknown),Andrew F. Bent,Wael E. Houssen,Sally L. Shirran,Matthew Fuszard,(unknown),Catherine H. Botting,Margaret C. M. Smith,Marcel Jaspars,James H. Naismith	23
20	A comparison of the accuracy of iTRAQ quantification by nLC-ESI MSMS and nLC-MALDI MSMS methods 2010 ·Journal of Proteomics ·Sally L. Shirran,Catherine H. Botting	51

About Sally L. Shirran

Sally L. Shirran is a scholar working on Equine, Pharmacology and Molecular Biology, having authored 54 papers that have together received 1.3k indexed citations. Recurring topics across this work include RNA modifications and cancer (6 papers), Microbial Natural Products and Biosynthesis (5 papers) and Neurogenetic and Muscular Disorders Research (5 papers). The work is most often cited by research in Pharmacology (469 citations), Molecular Biology (800 citations) and Biotechnology (81 citations). Sally L. Shirran has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Catherine H. Botting, James H. Naismith, Jesko Koehnke, Wael E. Houssen, Marcel Jaspars, Andrew F. Bent, Greg Mann, Perdita E. Barran, Tomáš Lébl and Tibor Harkany. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact